Take orally, with or without food. Swallow the tablet whole with a glass of water. Do not crush or chew.

Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2). COX-2 is responsible for the synthesis of prostaglandins, which are mediators of pain, inflammation, and fever. By inhibiting COX-2, Etoricoxib reduces prostaglandin production, thereby alleviating pain and inflammation.

• •Hypersensitivity to etoricoxib or any excipients
• •Active peptic ulceration or gastrointestinal bleeding
• •Severe hepatic impairment (Child-Pugh score >9)
• •Severe renal impairment (CrCl <30 mL/min)
• •Inflammatory bowel disease
• •Congestive heart failure (NYHA Class II-IV)
• •Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease
• •Previous history of bronchospasm, acute rhinitis, nasal polyps, angioedema, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
• •Pregnancy and lactation

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

In case of overdose, symptomatic and supportive treatment should be initiated. There is no specific antidote. Haemodialysis is unlikely to remove etoricoxib effectively.

Pregnancy Category C in the first and second trimesters, Category D in the third trimester. Avoid during pregnancy due to potential risk of premature closure of the ductus arteriosus and fetal renal dysfunction. Excreted in breast milk, therefore avoid during lactation.